BioSpace News Archive

Phlow Corp. is a U.S.-based, public benefit corporation that develops and domestically manufactures APIs and finished pharmaceutical products that are critical to the nation’s healthcare.

Elicio Therapeutics, Inc. is a clinical-stage biotechnology company advancing a pipeline of novel lymph node-targeted immunotherapies for the treatment of some of the most aggressive cancers.

Eitr Biologics, Inc., (Eitr) is a San Diego, CA based biotechnology company focused on the pursuit of novel next generation immunotherapeutics for the treatment of infectious diseases that are a current or emerging threat to public health.

DEFINING THE FUTURE OF RNA MEDICINES. Orbital Therapeutics is on a mission to enhance global health by unleashing the full potential of RNA medicines to treat human disease in ways that were not previously possible.

Aera was founded with a vision to unlock the potential of genetic medicines across a broad range of modalities and therapeutic areas. Our protein nanoparticle (PNP) delivery platform leverages the discovery of endogenous, human proteins that can self-assemble to form capsid-like structures and that can package and transfer nucleic acid cargo.

SonoThera is developing ultrasound-guided nonviral genetic therapies.

Abdera Therapeutics Inc. is a precision oncology company developing next-generation targeted radiation therapies - one of the most cutting-edge and highly promising areas of drug development. The company is built on a proprietary modular technology platform optimized for the delivery of radioisotopes to selectively destroy tumor cells while sparing healthy cells.

Convergent Therapeutics is a clinical-stage biotechnology company exploring the full potential of dual-targeted combination strategies to treat cancer. Convergent has developed a therapeutic platform that is capable of targeting validated and novel cancer antigens.

Delve Bio is a biotechnology company focused on improving precision medicine through cutting-edge genomic technology.

Linus Biotechnology is a patient-centric, breakthrough science, precision exposome medicine company. Our program pipeline comprises precision exposome medicine biomarkers and target discovery across disease domains for which historically no molecular endpoints have been available in medical practice or for clinical trials, including CNS (autism spectrum disorder, amyotrophic lateral sclerosis), gastroenterology (inflammatory bowel disease), renal disease and oncology.